Xilio Therapeutics Inc (XLO)
1.26
+0.08
(+6.78%)
USD |
NASDAQ |
May 06, 16:00
1.255
0.00 (0.00%)
After-Hours: 20:00
Xilio Therapeutics Enterprise Value: -0.7103M for May 3, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 03, 2024 | -0.7103M |
| May 02, 2024 | -5.192M |
| May 01, 2024 | -4.158M |
| April 30, 2024 | -5.537M |
| April 29, 2024 | -5.537M |
| April 26, 2024 | -3.813M |
| April 25, 2024 | -6.571M |
| April 24, 2024 | -4.847M |
| April 23, 2024 | -5.192M |
| April 22, 2024 | -3.468M |
| April 19, 2024 | -1.744M |
| April 18, 2024 | 2.737M |
| April 17, 2024 | 1.013M |
| April 16, 2024 | 3.427M |
| April 15, 2024 | 2.048M |
| April 12, 2024 | -0.7103M |
| April 11, 2024 | 5.495M |
| April 10, 2024 | 2.737M |
| April 09, 2024 | 3.771M |
| April 08, 2024 | 9.287M |
| April 05, 2024 | -0.0208M |
| April 04, 2024 | 0.3239M |
| April 03, 2024 | 3.427M |
| April 02, 2024 | 9.632M |
| April 01, 2024 | 11.36M |
| Date | Value |
|---|---|
| March 28, 2024 | -4.158M |
| March 27, 2024 | -23.74M |
| March 26, 2024 | -23.18M |
| March 25, 2024 | -22.06M |
| March 22, 2024 | -21.86M |
| March 21, 2024 | -21.99M |
| March 20, 2024 | -22.31M |
| March 19, 2024 | -22.48M |
| March 18, 2024 | -22.65M |
| March 15, 2024 | -22.48M |
| March 14, 2024 | -23.54M |
| March 13, 2024 | -22.06M |
| March 12, 2024 | -22.88M |
| March 11, 2024 | -20.50M |
| March 08, 2024 | -18.47M |
| March 07, 2024 | -19.33M |
| March 06, 2024 | -18.75M |
| March 05, 2024 | -19.46M |
| March 04, 2024 | -21.24M |
| March 01, 2024 | -21.50M |
| February 29, 2024 | -21.82M |
| February 28, 2024 | -23.17M |
| February 27, 2024 | -24.13M |
| February 26, 2024 | -24.82M |
| February 23, 2024 | -25.32M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-110.14M
Minimum
Jun 17 2022
598.63M
Maximum
Nov 16 2021
15.17M
Average
-14.48M
Median
Enterprise Value Benchmarks
| Gilead Sciences Inc | 76.06B |
| FibroGen Inc | -9.086M |
| Avalo Therapeutics Inc | 7.435M |
| IGM Biosciences Inc | 254.30M |
| AEON Biopharma Inc | -- |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -17.66M |
| Total Expenses (Quarterly) | 18.13M |
| EPS Diluted (Quarterly) | -0.64 |
| Earnings Yield | -221.5% |